CA2980478C - Compositions and methods for inhibiting kinases - Google Patents
Compositions and methods for inhibiting kinases Download PDFInfo
- Publication number
- CA2980478C CA2980478C CA2980478A CA2980478A CA2980478C CA 2980478 C CA2980478 C CA 2980478C CA 2980478 A CA2980478 A CA 2980478A CA 2980478 A CA2980478 A CA 2980478A CA 2980478 C CA2980478 C CA 2980478C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- virus
- mammal
- suffering
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562151659P | 2015-04-23 | 2015-04-23 | |
| US62/151,659 | 2015-04-23 | ||
| US201562182955P | 2015-06-22 | 2015-06-22 | |
| US62/182,955 | 2015-06-22 | ||
| PCT/US2016/028914 WO2016172528A1 (en) | 2015-04-23 | 2016-04-22 | Compositions and methods for inhibiting kinases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2980478A1 CA2980478A1 (en) | 2016-10-27 |
| CA2980478C true CA2980478C (en) | 2024-01-23 |
Family
ID=57144281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2980478A Active CA2980478C (en) | 2015-04-23 | 2016-04-22 | Compositions and methods for inhibiting kinases |
Country Status (6)
| Country | Link |
|---|---|
| US (8) | US9828370B2 (enExample) |
| EP (1) | EP3286179A4 (enExample) |
| JP (1) | JP6795518B2 (enExample) |
| AU (2) | AU2016252860B2 (enExample) |
| CA (1) | CA2980478C (enExample) |
| WO (1) | WO2016172528A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016252860B2 (en) | 2015-04-23 | 2020-09-17 | Inhibikase Therapeutics, Inc. | Compositions and methods for inhibiting kinases |
| WO2018081251A1 (en) * | 2016-10-25 | 2018-05-03 | Inhibikase Therapeutics, Inc. | Compositions and methods for inhibiting kinases |
| US10855891B2 (en) | 2016-11-21 | 2020-12-01 | Samsung Electro-Mechanics Co., Ltd. | Apparatus for controlling position of camera module |
| TW202039862A (zh) * | 2018-11-12 | 2020-11-01 | 美商藍印藥品公司 | 受體酪氨酸激酶(kit)基因突變 |
| JP2022523562A (ja) * | 2019-03-05 | 2022-04-25 | ホンイー アンド アソシエイツ エルエルシー | 神経変性疾患および癌の治療のための化合物 |
| CN115645393A (zh) * | 2020-02-26 | 2023-01-31 | 上海科技大学 | 二氢杨梅素在抗冠状病毒中的应用 |
| EP4138847A4 (en) * | 2020-04-24 | 2024-05-22 | Memorial Sloan Kettering Cancer Center | Targeted therapy for the treatment & prevention of life-threatening complications of infection |
| CN112552283A (zh) * | 2020-12-07 | 2021-03-26 | 天津羲泽润科技有限公司 | 一种新型替尼类药物的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1805748B (zh) * | 2003-06-13 | 2010-05-26 | 诺瓦提斯公司 | 作为raf激酶抑制剂的2-氨基嘧啶衍生物 |
| CA2662677C (en) * | 2006-09-05 | 2016-05-31 | Emory University | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof |
| WO2008070350A2 (en) * | 2006-10-27 | 2008-06-12 | The Board Of Regents Of The University Of Texas System | Methods and compositions related to wrapping of dehydrons |
| CN102406648A (zh) | 2010-09-21 | 2012-04-11 | 中国科学院生物物理研究所 | 甲磺酸伊马替尼在制备抗帕金森病药物中的应用 |
| KR20150008406A (ko) | 2012-05-15 | 2015-01-22 | 노파르티스 아게 | Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체 |
| WO2014055938A1 (en) | 2012-10-04 | 2014-04-10 | Inhibikase Therapeutics, Inc. | Novel compounds, their preparation and their uses |
| AU2016252860B2 (en) | 2015-04-23 | 2020-09-17 | Inhibikase Therapeutics, Inc. | Compositions and methods for inhibiting kinases |
| WO2018081251A1 (en) | 2016-10-25 | 2018-05-03 | Inhibikase Therapeutics, Inc. | Compositions and methods for inhibiting kinases |
-
2016
- 2016-04-22 AU AU2016252860A patent/AU2016252860B2/en active Active
- 2016-04-22 EP EP16783966.1A patent/EP3286179A4/en active Pending
- 2016-04-22 CA CA2980478A patent/CA2980478C/en active Active
- 2016-04-22 JP JP2017555374A patent/JP6795518B2/ja active Active
- 2016-04-22 US US15/136,497 patent/US9828370B2/en active Active
- 2016-04-22 WO PCT/US2016/028914 patent/WO2016172528A1/en not_active Ceased
-
2017
- 2017-11-07 US US15/805,693 patent/US10118923B2/en active Active
-
2018
- 2018-10-24 US US16/169,683 patent/US10344027B2/en active Active
- 2018-10-24 US US16/169,677 patent/US10316031B2/en active Active
-
2019
- 2019-06-26 US US16/452,828 patent/US10906896B2/en active Active
-
2020
- 2020-12-14 AU AU2020286339A patent/AU2020286339B2/en active Active
-
2021
- 2021-01-05 US US17/141,825 patent/US11407747B2/en active Active
-
2022
- 2022-06-24 US US17/849,141 patent/US11725005B2/en active Active
-
2024
- 2024-09-24 US US18/894,338 patent/US20250250266A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US10316031B2 (en) | 2019-06-11 |
| US10344027B2 (en) | 2019-07-09 |
| AU2020286339A1 (en) | 2021-01-21 |
| US20250250266A1 (en) | 2025-08-07 |
| US20180057488A1 (en) | 2018-03-01 |
| EP3286179A4 (en) | 2018-08-29 |
| US20160311816A1 (en) | 2016-10-27 |
| US10906896B2 (en) | 2021-02-02 |
| EP3286179A1 (en) | 2018-02-28 |
| AU2020286339B2 (en) | 2021-10-21 |
| AU2016252860A1 (en) | 2017-09-21 |
| US20230159514A1 (en) | 2023-05-25 |
| US11407747B2 (en) | 2022-08-09 |
| US9828370B2 (en) | 2017-11-28 |
| US20200031819A1 (en) | 2020-01-30 |
| US20210130343A1 (en) | 2021-05-06 |
| US20190055234A1 (en) | 2019-02-21 |
| WO2016172528A1 (en) | 2016-10-27 |
| AU2016252860B2 (en) | 2020-09-17 |
| JP6795518B2 (ja) | 2020-12-02 |
| JP2018513868A (ja) | 2018-05-31 |
| US20190119266A1 (en) | 2019-04-25 |
| US11725005B2 (en) | 2023-08-15 |
| US10118923B2 (en) | 2018-11-06 |
| CA2980478A1 (en) | 2016-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2980478C (en) | Compositions and methods for inhibiting kinases | |
| CA2771775C (en) | Compounds and compositions as protein kinase inhibitors | |
| JP7036939B2 (ja) | 癌細胞の成長抑制効果を示す新規なピリミジン誘導体及びそれを含む薬剤学的組成物 | |
| BRPI0720635A2 (pt) | Compostos orgânicos e seus usos | |
| WO2012088712A1 (en) | Compound as wnt signaling inhibitor, composition, and use thereof | |
| JP2019514951A (ja) | 増殖性疾患の治療に使用される置換２，４−ジアミノ−キノリン誘導体 | |
| US12286434B2 (en) | Pan-tropic entry inhibitors | |
| JP2023533616A (ja) | Ｍｎｋ阻害を示すピリジン－１，５－ジオン及びそれらの使用方法 | |
| AU2017350848B2 (en) | Compositions and methods for inhibiting kinases | |
| EP4373485A1 (en) | Cxcr4 modulators and uses related thereto | |
| CN117355507A (zh) | 用作lrrk2激酶抑制剂的嘧啶衍生物 | |
| WO2016127949A1 (zh) | 作为t790变异抑制剂的嘧啶衍生物 | |
| WO2010083645A1 (en) | PYRIMIDO[5,4-e][1,2,4]TRIAZINES AND USES THEREOF | |
| KR20060033818A (ko) | 신규한 2-(2-아미노-4-피리미디닐)-4-아미노페놀 유도체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210421 |
|
| EEER | Examination request |
Effective date: 20210421 |
|
| EEER | Examination request |
Effective date: 20210421 |
|
| EEER | Examination request |
Effective date: 20210421 |
|
| EEER | Examination request |
Effective date: 20210421 |
|
| EEER | Examination request |
Effective date: 20210421 |
|
| EEER | Examination request |
Effective date: 20210421 |
|
| EEER | Examination request |
Effective date: 20210421 |